Why is Pfizer (NYSE:PFE) stock in focus as new immunology trial data lands?
Why is Pfizer (NYSE:PFE) stock in focus as new immunology trial data lands? Kalkine Media
Covered in this story
Analyst targets on Pfizer
- HSBC: $23.7 → $28 by Jul 2027 · Hold via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 49 stories mentioning Pfizer, the earliest published 22 May 2026.
Summary aggregated from Kalkine Media's public RSS feed. The full reporting belongs to Kalkine Media — please read it on their site.